Clinical Trial Update: Real-World Clinical Outcomes and Toxicity in Metastatic Breast Cancer Patients Treated With First or Second Line CDK 4/6 Inhibitors and Endocrine Therapy

View source ↗

Summary

This clinical trial update reports real-world outcomes and toxicity in metastatic breast cancer patients treated with first- or second-line CDK4/6 inhibitors in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Abemaciclib (abemaciclib)
• Anastrozole (Anastrozole)
• Exemestane (Exemestane)
• Fulvestrant (fulvestrant)
• Letrozole (letrozole)
• Palbociclib (palbociclib)
• Ribociclib (ribociclib)

Snippet

Sponsor: Ain Shams University | Conditions: Toxicity, Drug, Progression, Disease | Status: COMPLETED